Trials / Active Not Recruiting
Active Not RecruitingNCT04857372
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Detailed description
This is a phase I, open-label, multi-center study of IAG933 as a single agent consisting of a dose escalation part, followed by a dose expansion part. The escalation part will characterize the safety and tolerability. After the determination of the recommended dose/maximum tolerated dose, dose expansion will assess the preliminary anti-tumor activity in defined patient populations and further assess the safety and tolerability at RD/MTD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IAG933 | Capsule |
Timeline
- Start date
- 2021-10-21
- Primary completion
- 2026-09-04
- Completion
- 2026-09-04
- First posted
- 2021-04-23
- Last updated
- 2025-09-19
Locations
16 sites across 11 countries: United States, Australia, Canada, France, Germany, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04857372. Inclusion in this directory is not an endorsement.